RFA-HL-26-017-Full-Announcement.html

This document is a Request for Applications (RFA) for the NIH Catalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed) grant opportunity.

The goal of this initiative is to provide early-stage translational support for activities required to identify and characterize potential therapeutic candidates and combination products to treat heart, lung, blood, and sleep disorders. The grant is offered by the Department of Health and Human Services' National Institutes of Health. Eligible applicant types include government entities, higher education institutions, nonprofits, small businesses, and tribes. Funding will be provided through grants under the NIH's Lung Diseases Research, Cardiovascular Diseases Research, Blood Diseases and Resources Research, and National Center on Sleep Disorders Research programs. The opportunity has no set award amounts or number of awards. Applications are due by the listed deadline, with an anticipated award start date.